Why Amentum Stock Is Crashing This Week

Amentum reported Q1 FY2026 adjusted EPS of $0.54, beating the $0.52 consensus, but revenue missed at $3.24 billion versus $3.32 billion expected and free cash flow swung to a negative $142 million from +$102 million a year earlier. Management guided FY2026 revenue to $13.95–14.3 billion (~+3% YoY) and adjusted EBITDA to $1.10–1.14 billion (~+5% YoY); despite the modest growth outlook, shares tumbled roughly 19.9% during the week and now trade at about 75.2x trailing earnings, signaling investor caution and prompting some to prefer other nuclear-energy exposures.

Analysis

Market structure: Amentum’s Q1 revenue miss, negative FCF (-$142m vs +$102m prior) and 75x trailing P/E shift marginal pricing power to specialty nuclear OEMs and pure-play suppliers (e.g., BWXT, HII) that sell components and reactors rather than broad systems integration. Integrators face fixed‑price contract risk and working capital strains; government prime contractors with large backlogs but weak cash conversion are vulnerable to multiple compression and credit spread widening. Cross‑asset: expect higher implied volatility and wider corporate credit spreads for AMTM peers; upward pressure on uranium/steel prices benefits miners and fabricators, while defensive bond demand may increase in near term.

Risk assessment: Tail risks include a major government contract cancellation or a material subcontractor performance failure that forces re‑scopes (months) and sharp margin downgrades (high impact, low prob). Immediate (days) risk is continued share volatility; short‑term (3–6 months) risk is continued cash burn and working capital hits; long‑term (2–5 years) depends on federal nuclear program funding and awarded backlog conversion. Hidden dependencies: backlog quality (T&M vs fixed price), receivables cadence, and DOEschedule of awards; catalysts include contract awards, quarterly FCF swing to positive, or DoD/DOE budget updates.

Trade implications: Bias short AMTM given valuation and cash profile while selectively long pure‑play nuclear suppliers and utilities with contracted builds. Preferred instruments are 3–9 month AMTM put spreads to limit premium, and 6–12 month call spreads on BWXT/HII to play structural demand. Implement pair trades (long BWXT or HII, short AMTM) sized 2–3% each, horizon 3–12 months, with defined stops and news‑based exit triggers.

Contrarian angles: The market may be overselling narrative despite an EPS beat — if FCF turns positive next quarter or management narrows receivables days by >20% QoQ, AMTM could rebound sharply (short squeeze risk). Consensus underweights backlog composition and contract type; a positive re‑pricing of backlog (more T&M) would materially reduce downside. Historical parallels: integrator selloffs after single‑quarter misses often reverse when cash flow stabilizes, so maintain size discipline and use option structures to asymmetrically express view.

Key Decisions for Investors

• Establish a 2.5% portfolio short position in AMTM (or equivalent via 3‑month put spread: buy ATM puts, sell 25–30% OTM puts) with a target -35% downside from current levels and a hard stop if AMTM rallies +15% from entry; horizon 3–6 months to capture FCF/guide‑driven repricing.
• Initiate a 2–3% long position in BWXT (BWXT) or Huntington Ingalls (HII) funded by the AMTM short; use 6–12 month 20–40% OTM call spreads to limit premium and target 30–60% upside on nuclear capex acceleration over 6–12 months.
• Execute a pair trade: long 3% BWXT (or HII) and short 3% AMTM, rebalancing monthly; close the pair if AMTM FCF turns positive (>0) or if BWXT/HII miss consensus revenue by >5% (protects vs execution risk).
• Reduce exposure to high‑multiple systems integrators/engineering names trading >40x forward EPS by 3–5% and redeploy into uranium miners or contractors if uranium spot price rises >20% within 90 days, or into BWXT/HII if DOE/DoD awards increase backlog by >10%.